Physician profile
Kamara E Garner
NPI 1053349456
$7,767.27
in general payments reported to CMS, 2019-2025
40 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $151 · 2021: $1,107 · 2022: $1,545 · 2023: $1,427 · 2024: $1,525 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,470 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,469.87 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,088.55 | 2021-2025 | |
| Novo Nordisk INC | $889.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $797.01 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $709.78 | 2019-2025 | |
| Lilly USA, LLC | $587.07 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $473.25 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $423.73 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.07 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $218.58 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $195.95 | 2022 | |
| Amarin Pharma, INC. | $193.90 | 2019-2021 | |
| Exact Sciences Corporation | $170.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $144.96 | 2021-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $141.04 | 2025 | Rexulti |
| Astellas Pharma US INC | $123.64 | 2019-2025 | Veozah |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamara Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.